| Study, Year | Screening Type | Screening Interval (Months) | Number of Screens | Positive Test Results (%) | Recommendation for Followup Based on LDCT (Number) | Surgery for Diagnosis (Benign) (Number) | Lung Cancerb (%) | Stage 1 Disease (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HRCT | Referral | Biopsy | ||||||||
| Diederich et al, 200253 | Baseline LDCT | 817 | 350 (43) | 269 | 29 | 13 | 1 (1) | 11 (1.3) (1 interval) |
58 | |
| Henschke et al, 1999, 200154,55 | Baseline LDCT | 6-18 | 1,000 | 237 (24) | 233 | 104 | 27 | 0 | 31 (3.1) | 85 |
| Incidence LDCTa | 1,184 | 40 | 40 | NR | 9 | NR | 9 (0.9) | 67 | ||
| Baseline CXR | 1,000 | 68 (6.8) (33) (3.3)c |
33 | NR | NR | 0 | 7 (0.7) | |||
| Nawa et al, 200256 | Baseline LDCT | 12 | 7,956 | 2,099 (26.4) | 541 | 64 | NR | NR | 36 (0.5) | 86 |
| Incidence LDCTa | 5,568 | NR | 148 | 7 | NR | NR | 4 (0.1) | 100 | ||
| Sone et al, 200158 | Baseline LDCT | 12 | 5,483 | 279 (5.1) | 266 | NR | NR | NR (7) | 22 (0.4) | 100 |
| Incidence LDCTa | 8303b | 309 | 297 | NR | NR | NR(9) | 37 (0.6) | 86 | ||
| Sobue et al, 200259 | Baseline LDCT | 6 | 1,611 | 186 (11.5) | 186 | 25 | 21 | 0 | 13 (0.8) | 77 |
| Incidence LDCTa | 7,891 | 721 | 721 | 57 | 35 | 1 (0) | 19 (0.2) | 79 | ||
| Baseline CXR | 1,611 7,891 |
55 (3.4) 202 |
22 89 |
9 7 |
8 4 |
0 0 |
5 (0.3) 3 (0.2) |
60 0 |
||
| Swensen et al, 2002, 200361,62 | Baseline LDCT | 12 | 1,520 | 782 (51.4) | NR | NR | NR | 27 (1.8)d | ||
| Combined data | NR (8) | 66 | ||||||||
| Incidence LDCTa | 2,916 | 336 | NR | NR | NR | 11 (0.7) (+ 2 interval)d |
||||
Notes: CXR, chest x-ray; HRCT, high-resolution computerized tomography; LDCT, low-dose computerized tomography; NR, not reported.
a All data presented by individual except incidence, which indicates screening tests performed.
b Percentage of lung cancer for incidence = cases of lung cancer identified with incidence screening/cases of lung cancer in cohort minus cases of prevalence cancer.
c After LDCT.
d One case of malignant disease.